Chimeric Antigen Receptor Car T Cell Immunotherapy Competitive Landscape Pipeline Market Analysis

DelveInsight’s, “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2017”, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Chimeric Antigen Receptor (CAR) T cell Immunotherapy. This report provides information on the therapeutic development based on Chimeric Antigen Receptor (CAR) T cell Immunotherapy mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight’s Report also assesses the Chimeric Antigen Receptor (CAR) T cell Immunotherapy therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

Scope

• The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy

• The report provides the marketed drugs information including its sales, development activities and details of patent expiry

• The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy

• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

• Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

• The report reviews key players involved in the therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy and also provide company profiling

• The report also gives the information of dormant pipeline projects

• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages

• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to Buy

• Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

• Complete MOA intelligence and complete understanding over therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy

• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.

• Devise corrective measures for pipeline projects by understanding Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline depth and focus of Indication therapeutics

• Developing strategic initiatives to support your drug development activities.

• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.

• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Report Introduction

Executive Summary Snapshot

Executive Summary

Introduction

Chimeric antigen receptor (CAR) T-cells

History

CARs and Generations

Advantages of CAR-T cells

Adverse Events with CAR T-cell Therapy

Limitations of Existing Technologies for CAR T-Cells

CAR-T Cell Therapy-Analysis

CAR-T Collaboration Deals

CAR-T Cells Therapy Collaborations and Deal Year

Collaborations & Deal Value Trends

Companies collaborations for future developments

CAR-T Acquisitions Deals

CAR-T Cells Therapy Acquisitions Trends

CAR-T Cells Therapy Acquisitions Offerings by Big Giants

New facilityfor the development of CAR-T cells

JCAR015: Major Set Back for Juno Therapeutics

CAR-T Licensing Opportunities

Pipeline Scenario

Pipeline Products under Development-An Overview

Pipeline Products under Development by Company

CAR T-cells Therapeutic Areas & Companies

CAR-T cells Targeted Antigens

CAR-T Therapies-Clinical trials & Completion Year

CAR T-cell Technologies & Companies Involved

CAR-T Safety Switches & Company involved

Companies with Upcoming CAR-T Therapeutics

Pipeline Profiles

Other Active Companies

Miltenyi Biotec

ZMKS International Cancer Therapies Biotechnologies Co. Ltd.

Upcoming Technologies Better than CARs

Market Drivers

Market Barriers

SWOT Analysis

Report Methodology

Consulting Services

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – Company Collaborations and Deal Year, 2017

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2017

Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017

Table 5: Companies CAR-T Investment for future developments, 2017

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017

Table 7:Companies open for licensing and collaborations, 2017

Table 8:Number of Products under Development, 2017

Table 9:Number of Products under Development by Companies, 2017

Table 10:Number of Products under Development by Indication, 2017

Table 11:Number of Products Targeting CD19 Antigen, 2017

Table 12:Number of Products Targeting Other Antigens, 2017

Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017

Table 14:CAR T-cell Companies and Technologies, 2017

Figure 1: Companies Collaborations vs. Financial year, 2017

Figure 2: Number of Companies Collaborations, 2017

Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017

Figure 4: Number of Products under Development, 2017

Figure 5: Number of Products under Development by Companies, 2017

Figure 6: Number of Products under Development by Indication, 2017

Figure 7: CAR-T cell Targeted Antigens (%), 2017

Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017

Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017

Figure 10:CAR T-cell Companies and Technologies, 2017

Arbele Limited

Apceth

Aurora Biopharma

Autolus Limited

Avacta Life Sciences Limited

Beijing Biohealthcare Biotechnology Co.,Ltd

Beijing Doing Biomedical Co., Ltd.

Beijing Sanwater Biological Technology Co., Ltd.

Bellicum Pharmaceuticals Inc.

Benitec Biopharma Limited

BioAtla, LLC

BioInvent International

Bluebird bio

CARMA Therapeutics

Carsgen Therapeutics

Cartherics Pty Ltd

Celgene Corporation 

Cell Medica

Cellectis

Cellular Biomedicine Group Inc.

Celyad

Chimeric Therapeutics Ltd.

Cytomx Therapeutics

Enlivex Therapeutics Ltd

Eureka Therapeutics, Inc

F1 Oncology

Fate Therapeutics

Formula Pharmaceuticals

GlaxoSmithKline plc

Hebei Senlang Biotechnology Inc., Ltd.

iCarTAB BioMed Inc

iCell Gene Therapeutics

Immunocore Limited

Innovative Cellular Therapeutics Co., Ltd.

Intellia Therapeutics

Juno Therapeutics, Inc.

Kite Pharma Inc.

Les Laboratoires Servier

Marino Biotechnology Co., Ltd.

Maxcyte

Mimivax LLC

MolMed S.p.A.

Mustang Bio ( Subsidiary of Fortress Biotech)

Nohla Therapeutics Inc.

Novartis Pharmaceuticals

OncoTAb, Inc.

Oncternal Therapeutics, Inc

Oxford Biomedica

Partikula LLC

"PersonGen Biomedicine (Suzhou) Co., Ltd.

"

Poseida Therapeutics, Inc.

Protheragen 

Regen BioPharma, Inc.

Shanghai GeneChem Co., Ltd.

Shire plc

Sinobioway Cell Therapy Co., Ltd.

Sirtex Medical

Sorrento Therapeutics

SymVivo

Takara Bio

Tessa Therapeutics Pte Ltd.

The Beijing Pregene Science and Technology Company, Ltd.

Theravectys

TILT Biotherapeutics Ltd

VorBio Pharma

Wuhan Sian Medical Technology Co., Ltd

Zhongyuan Xiehe Cell Gene Engineering Co (Union Stem cell & gene engineering Co.LTD)

Ziopharm Oncology Inc. and Intrexon

  • Tags:
  • "• CAR-T cell Therapy Pipeline scen...

Forward to Friend

Need A Quote